Liminatus Pharma, Inc.
LIMN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001971387
No open-market purchases or sales by Liminatus Pharma, Inc. insiders were filed in the last 90 days; 14 institutions reported holding it in 13F filings for Q2 2026, worth $105.1K in total; no superinvestor holds it.
Other share classesLIMNW
13F holders, Q1 2026
Institutional positions in Liminatus Pharma, Inc. as of Mar 31, 2026. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 15
- +4 vs. Q4 2025
- Shares held
- 1.48M
- +1.23M (+505.3%) vs. Q4 2025
- Total value
- $253.8K
- +$105.0K (+70.6%) vs. Q4 2025
- New holders
- 6
- 5 more added
- Sold out
- 2
- 3 more reduced
1 institution that held it in Q4 2025 haven't filed for Q1 2026 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q4 2025: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LIMN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 14 | $105.1K |
| Q1 2026 | 15 | $253.8K |
| Q4 2025 | 12 | $193.5K |
| Q3 2025 | 10 | $437.4K |
| Q2 2025 | 10 | $2.28M |
| Q1 2025 | 0 | $0 |
| Q4 2024 | 0 | $0 |
| Q3 2024 | 0 | $0 |
| Q2 2024 | 0 | $0 |
| Q1 2024 | 0 | $0 |
| Q4 2023 | 0 | $0 |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q1 2026
Shares, value and share of portfolio for each institution holding Liminatus Pharma, Inc.; share changes are against Q4 2025.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Farther Finance Advisors, LLC | 14 | $2 | 0.00% | −17−54.8% | Reduced |
| Citigroup Inc | 6,769 | $1.16K | 0.00% | +6,768+676,800.0% | Added |
| Tower Research Capital LLC (TRC) | 7,567 | $1.30K | 0.00% | −1,336−15.0% | Reduced |
| BlackRock, Inc. | 13,254 | $2.28K | 0.00% | −10.0% | Reduced |
| State Street Corp | 19,000 | $3.27K | 0.00% | 00.0% | Unchanged |
| Two Sigma Securities, LLC | 22,039 | $3.79K | 0.00% | +10,164+85.6% | Added |
| Vanguard Fiduciary Trust Co | 22,984 | $3.95K | 0.00% | +22,984 | New |
| Virtu Financial LLC | 27,468 | $5.00K | 0.00% | +27,468 | New |
| JustInvest LLC | 34,706 | $5.97K | 0.00% | +34,706 | New |
| Vanguard Capital Management LLC | 50,440 | $8.68K | 0.00% | +50,440 | New |
| UBS Group AG | 54,578 | $9.39K | 0.00% | +35,183+181.4% | Added |
| Jane Street Group, LLC | 71,318 | $12.3K | 0.00% | +71,318 | New |
| Geode Capital Management, LLC | 117,783 | $20.2K | 0.00% | +52,732+81.1% | Added |
| Cygnus Capital Advisors, LLC | 350,000 | $60.0K | 0.04% | +350,000 | New |
| Citadel Advisors LLC | 677,518 | $116.5K | 0.00% | +606,588+855.2% | Added |
| Two Sigma Investments, LP | 0 | $0 | 0.00% | −35,284−100.0% | Sold out |
| Bank of America Corp | 0 | $0 | 0.00% | −44−100.0% | Sold out |
| Vanguard Group Inc | – | – | – | – | Not filed |